Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains
Mandate

Vinge advises SJ in connection with agreement governing restoration of SJ 2000 trains

January 16, 2014

SJ is making one of the largest commitments in the company’s 150-year history by investing in a comprehensive renewal and restoration programme for its fleet of SJ 2000 trains. SJ has entered into an agreement with ABB concerning the initial technical restoration of the entire fleet of SJ 2000 trains (previously X 2000). This phase of the renovation will cost approximately SEK 1.4 billion. The first newly-renovated SJ 2000 train will be put into operation in 2016, although the renewal and restoration programme will continue until 2019. The renovation is anticipated to reduce energy consumption by approximately 10 per cent.

Vinge’s team consisted of, among others, partners Eva Fredrikson and Björn Gustavsson and associate Mikael Satama Grönberg.   

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026